B
STSA

Bailard’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

Bailard’s Portfolio STSA Stock Details STSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-20,500
Closed -$145K – 780
2021
Q2 		$145K Buy
+20,500
New +$111K 0.01% 694
2020
Q4 		– Sell
-38,600
Closed -$150K – 697
2020
Q3 		$150K Buy
+38,600
New +$776K 0.01% 500

Other funds holding STSA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bailard's STSA Position: Q3 2021 in Review

Bailard sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q3 2021, closing a stake of 20,500 shares — an estimated $145K sold.

Bailard first reported a position in STSA in Q3 2020 and held it in 2 quarters. The position peaked at $150K in Q3 2020. 45 funds tracked by Wall St. Rank hold STSA as of Q3 2021.

  • Bailard reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Bailard sold 20,500 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q3 2021, an estimated $145K.
  • Bailard first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 2 quarters.
  • Bailard's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $150K in Q3 2020.
  • 45 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q3 2021.

Based on Bailard's 13F filing for Q3 2021, filed 15 Nov 2021.